Media stories about EntreMed (NASDAQ:CASI) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. EntreMed earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.5855932579515 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
CASI has been the subject of several analyst reports. BidaskClub downgraded shares of EntreMed from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 14th. HC Wainwright reaffirmed a “buy” rating and set a $4.50 price target on shares of EntreMed in a research note on Monday, January 29th. Finally, ValuEngine raised shares of EntreMed from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd.
Shares of NASDAQ CASI opened at $6.73 on Friday. EntreMed has a twelve month low of $0.91 and a twelve month high of $7.59. The firm has a market cap of $506.52, a P/E ratio of -37.39 and a beta of 0.90. The company has a quick ratio of 8.66, a current ratio of 8.66 and a debt-to-equity ratio of 0.04.
In other news, major shareholder China Growth Fund Idg-Accel II bought 3,086,418 shares of the stock in a transaction that occurred on Wednesday, March 21st. The stock was acquired at an average price of $3.19 per share, with a total value of $9,845,673.42. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Wei-Wu He bought 3,086,419 shares of the stock in a transaction that occurred on Monday, March 19th. The shares were purchased at an average cost of $3.24 per share, with a total value of $9,999,997.56. Following the purchase, the director now directly owns 847,527 shares of the company’s stock, valued at $2,745,987.48. The disclosure for this purchase can be found here. 24.52% of the stock is owned by company insiders.
WARNING: “EntreMed (CASI) Getting Somewhat Favorable Press Coverage, Report Finds” was first posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://dakotafinancialnews.com/2018/04/13/entremed-casi-getting-somewhat-favorable-press-coverage-report-finds.html.
CASI Pharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma.
Receive News & Ratings for EntreMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EntreMed and related companies with MarketBeat.com's FREE daily email newsletter.